Janus kinase 3 (JAK3) (JAK3)

Janus kinase 3 (JAK3) is a cytoplasmic non-receptor tyrosine kinase that plays a pivotal role in the signaling pathways of the common gamma chain (γc) cytokine receptors, including those for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 (UniProt P52333). It is predominantly expressed in hematopoietic cells, particularly T-cells, B-cells, and natural killer (NK) cells, making it a critical regulator of immune system development and function (PubMed: 29073245). Upon cytokine binding to its receptor, JAK3 is activated and phosphorylates STAT proteins, which then dimerize and translocate to the nucleus to initiate gene transcription (StatPearls: Janus Kinase Inhibitors). Dysregulation of JAK3 signaling is implicated in various pathologies; loss-of-function mutations lead to autosomal recessive severe combined immunodeficiency (SCID), while gain-of-function mutations or over-activation are linked to autoimmune diseases and hematologic malignancies (NCBI Gene: 3718). Therapeutic targeting of JAK3 with small-molecule inhibitors like tofacitinib and the more selective ritlecitinib has proven effective in treating conditions such as rheumatoid arthritis and alopecia areata (FDA: Xeljanz, Litfulo). Because of its restricted expression and specific association with the γc chain, JAK3 is considered a highly attractive target for immunosuppressive therapy with potentially fewer systemic side effects than pan-JAK inhibitors (PubMed: 30107730).

Other names

JAK-3L-JAKLeukocyte Janus kinaseTyrosine-protein kinase JAK3

Inhibition of the catalytic activity of the kinase domain, preventing the phosphorylation of Signal Transducers and Activators of Transcription (STAT) proteins and blocking downstream cytokine-mediated signaling pathways (PubMed: 30107730).